Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan S Jensen

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
The Canadian Journal of Cardiology|December 6, 2014
Osteoprotegerin levels change during STEMI and reflect cardiac functionSøren Lindberg, Jan S Jensen, Søren Hoffmann, et al.
American Journal of Hypertension|December 19, 2009
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart StudyCamilla Asferg, Rasmus Møgelvang, Allan Flyvbjerg, et al.
European Heart Journal. Acute Cardiovascular Care|December 6, 2014
Nationwide trends in use and timeliness of diagnostic coronary angiography in acute coronary syndromes from 2005 to 2011: Does distance to invasive heart centres matter?Kim W Hansen, Rikke Sørensen, Mette Madsen, et al.
Cardiology|September 12, 2012
Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionSune Pedersen, Rasmus Mogelvang, Mette Bjerre, et al.
Circulation. Cardiovascular Interventions|February 2, 2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonanceJacob Lønborg, Henning Kelbaek, Niels Vejlstrup, et al.
American Heart Journal|December 15, 2010
ST-Segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonanceJacob Lønborg, Lene Holmvang, Henning Kelbæk, et al.
Blood Pressure|October 25, 2011
Interaction between leptin and leisure-time physical activity and development of hypertensionCamilla Asferg, Rasmus Møgelvang, Allan Flyvbjerg, et al.
Journal of Interventional Cardiology|December 24, 2010
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trialAllan Iversen, Ulrik Abildgaard, Anders Galloe, et al.
The Journal of Invasive Cardiology|December 25, 2010
Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registryAllan Z Iversen, Sune H Pedersen, Christian Joens, et al.
International Journal of Cardiology|July 17, 2016
Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and functionPeter G Jørgensen, Magnus T Jensen, Rasmus Mogelvang, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
The Canadian Journal of Cardiology|December 6, 2014
Osteoprotegerin levels change during STEMI and reflect cardiac functionSøren Lindberg, Jan S Jensen, Søren Hoffmann, et al.
American Journal of Hypertension|December 19, 2009
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart StudyCamilla Asferg, Rasmus Møgelvang, Allan Flyvbjerg, et al.
European Heart Journal. Acute Cardiovascular Care|December 6, 2014
Nationwide trends in use and timeliness of diagnostic coronary angiography in acute coronary syndromes from 2005 to 2011: Does distance to invasive heart centres matter?Kim W Hansen, Rikke Sørensen, Mette Madsen, et al.
Cardiology|September 12, 2012
Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionSune Pedersen, Rasmus Mogelvang, Mette Bjerre, et al.
Circulation. Cardiovascular Interventions|February 2, 2010
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonanceJacob Lønborg, Henning Kelbaek, Niels Vejlstrup, et al.
American Heart Journal|December 15, 2010
ST-Segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonanceJacob Lønborg, Lene Holmvang, Henning Kelbæk, et al.
Blood Pressure|October 25, 2011
Interaction between leptin and leisure-time physical activity and development of hypertensionCamilla Asferg, Rasmus Møgelvang, Allan Flyvbjerg, et al.
Journal of Interventional Cardiology|December 24, 2010
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trialAllan Iversen, Ulrik Abildgaard, Anders Galloe, et al.
The Journal of Invasive Cardiology|December 25, 2010
Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registryAllan Z Iversen, Sune H Pedersen, Christian Joens, et al.
International Journal of Cardiology|July 17, 2016
Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and functionPeter G Jørgensen, Magnus T Jensen, Rasmus Mogelvang, et al.
Pageof 7